Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Free Cash Flow (2016 - 2025)

Bio-Techne (TECH) has 17 years of Free Cash Flow data on record, last reported at $76.5 million in Q4 2025.

  • For Q4 2025, Free Cash Flow fell 1.34% year-over-year to $76.5 million; the TTM value through Dec 2025 reached $223.0 million, down 12.3%, while the annual FY2025 figure was $256.6 million, 8.66% up from the prior year.
  • Free Cash Flow reached $76.5 million in Q4 2025 per TECH's latest filing, up from $22.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $110.7 million in Q2 2021 and bottomed at $22.2 million in Q3 2025.
  • Average Free Cash Flow over 5 years is $63.1 million, with a median of $61.3 million recorded in 2021.
  • Peak YoY movement for Free Cash Flow: soared 303.76% in 2021, then tumbled 59.39% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $90.8 million in 2021, then plummeted by 35.84% to $58.3 million in 2022, then rose by 17.12% to $68.3 million in 2023, then rose by 13.59% to $77.5 million in 2024, then decreased by 1.34% to $76.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $76.5 million in Q4 2025, $22.2 million in Q3 2025, and $93.3 million in Q2 2025.